KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.

J Clin Oncol · 2025-Dec-20 · PMID 41037766

Panel C提取完成待 EXE 对齐验证

overall survival

FIG 2. Kaplan-Meier estimates of (A) duration of complete response, (B) centrally assessed PFS, and (C) OS in the primary analysis (intent-to-treat population). GemOx, gemcitabine plus oxaliplatin; Mosun, mosunetuzumab; NE, not estimable; OS, overall survival; PFS, progression-free survival; Pola, polatuzumab vedotin; R, rituximab.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分1.00
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-18T19:38:09+00:00